Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

Get the Message

Conventional prophylactic vaccines have had a huge impact on the treatment and prevention of many diseases, but mRNA-based approaches – utilising these molecules’ highly versatile, non-toxic and temperature-insensitive characteristics – may be the way forward, says CureVac’s Ingmar Hoerr.

Ingmar Hoerr, CureVac (December 2014)

Keywords: Prophylactic vaccines, Cancer immunotherapy, Messenger RNA, Good Manufacturing, Practice, Toll-like receptors, Humoral and cellular responses

    View full article    |    Back to Biopharma section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |